Optimizing chemotherapy-free survival for the ER/HER2-positive metastatic breast cancer patient

Stefan Glück, Carlos L. Arteaga, C. Kent Osborne

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

The recent incremental advances made in the treatment of metastatic breast cancer have elicited potential for survival extension in this treatable, yet incurable, population of breast cancer patients. Clinicians have focused on targeted therapies, which aim at signaling receptors such as the human epidermal receptor superfamily, the estrogen receptor, VEGF, the insulin-like growth factor receptor, the hepatocyte growth factor receptor (cMET), phosphoinositide 3-kinase, mTOR, and many others.

Original languageEnglish
Pages (from-to)5559-5561
Number of pages3
JournalClinical Cancer Research
Volume17
Issue number17
DOIs
StatePublished - Sep 1 2011
Externally publishedYes

Fingerprint

Proto-Oncogene Proteins c-met
Breast Neoplasms
Somatomedin Receptors
Drug Therapy
1-Phosphatidylinositol 4-Kinase
Survival
Estrogen Receptors
Vascular Endothelial Growth Factor A
Therapeutics
Population

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Optimizing chemotherapy-free survival for the ER/HER2-positive metastatic breast cancer patient. / Glück, Stefan; Arteaga, Carlos L.; Osborne, C. Kent.

In: Clinical Cancer Research, Vol. 17, No. 17, 01.09.2011, p. 5559-5561.

Research output: Contribution to journalArticle

Glück, Stefan ; Arteaga, Carlos L. ; Osborne, C. Kent. / Optimizing chemotherapy-free survival for the ER/HER2-positive metastatic breast cancer patient. In: Clinical Cancer Research. 2011 ; Vol. 17, No. 17. pp. 5559-5561.
@article{cdd527c4c79c406cb438f9fb9e0dda8b,
title = "Optimizing chemotherapy-free survival for the ER/HER2-positive metastatic breast cancer patient",
abstract = "The recent incremental advances made in the treatment of metastatic breast cancer have elicited potential for survival extension in this treatable, yet incurable, population of breast cancer patients. Clinicians have focused on targeted therapies, which aim at signaling receptors such as the human epidermal receptor superfamily, the estrogen receptor, VEGF, the insulin-like growth factor receptor, the hepatocyte growth factor receptor (cMET), phosphoinositide 3-kinase, mTOR, and many others.",
author = "Stefan Gl{\"u}ck and Arteaga, {Carlos L.} and Osborne, {C. Kent}",
year = "2011",
month = "9",
day = "1",
doi = "10.1158/1078-0432.CCR-10-2051",
language = "English",
volume = "17",
pages = "5559--5561",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "17",

}

TY - JOUR

T1 - Optimizing chemotherapy-free survival for the ER/HER2-positive metastatic breast cancer patient

AU - Glück, Stefan

AU - Arteaga, Carlos L.

AU - Osborne, C. Kent

PY - 2011/9/1

Y1 - 2011/9/1

N2 - The recent incremental advances made in the treatment of metastatic breast cancer have elicited potential for survival extension in this treatable, yet incurable, population of breast cancer patients. Clinicians have focused on targeted therapies, which aim at signaling receptors such as the human epidermal receptor superfamily, the estrogen receptor, VEGF, the insulin-like growth factor receptor, the hepatocyte growth factor receptor (cMET), phosphoinositide 3-kinase, mTOR, and many others.

AB - The recent incremental advances made in the treatment of metastatic breast cancer have elicited potential for survival extension in this treatable, yet incurable, population of breast cancer patients. Clinicians have focused on targeted therapies, which aim at signaling receptors such as the human epidermal receptor superfamily, the estrogen receptor, VEGF, the insulin-like growth factor receptor, the hepatocyte growth factor receptor (cMET), phosphoinositide 3-kinase, mTOR, and many others.

UR - http://www.scopus.com/inward/record.url?scp=80052516349&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052516349&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-10-2051

DO - 10.1158/1078-0432.CCR-10-2051

M3 - Article

VL - 17

SP - 5559

EP - 5561

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 17

ER -